Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T. Di Leo A, et al. Among authors: dharan b. Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7. Lancet Oncol. 2018. PMID: 29223745 Clinical Trial.
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Baselga J, et al. Among authors: dharan b. Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30. Lancet Oncol. 2017. PMID: 28576675 Free PMC article. Clinical Trial.
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R, Hirawat S. Massacesi C, et al. Among authors: dharan b. Onco Targets Ther. 2016 Jan 7;9:203-10. doi: 10.2147/OTT.S89967. eCollection 2016. Onco Targets Ther. 2016. PMID: 26793003 Free PMC article. Review.
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
Tan DSW, Felip E, de Castro G, Solomon BJ, Greystoke A, Cho BC, Cobo M, Kim TM, Ganguly S, Carcereny E, Paz-Ares L, Bennouna J, Garassino MC, Schenker M, Kim SW, Brase JC, Bury-Maynard D, Passos VQ, Deudon S, Dharan B, Song Y, Caparica R, Johnson BE. Tan DSW, et al. Among authors: dharan b. J Clin Oncol. 2024 Jan 10;42(2):192-204. doi: 10.1200/JCO.23.00980. Epub 2023 Dec 1. J Clin Oncol. 2024. PMID: 38039427 Clinical Trial.
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Paz-Ares L, Goto Y, Wan-Teck Lim D, Halmos B, Chul Cho B, Cobo M, Luis González Larriba J, Zhou C, Demedts I, Atmaca A, Baka S, Mookerjee B, Portella S, Zhu Z, Wu J, Demanse D, Dharan B, Reck M. Paz-Ares L, et al. Among authors: dharan b. Lung Cancer. 2024 Mar;189:107451. doi: 10.1016/j.lungcan.2023.107451. Epub 2024 Jan 16. Lung Cancer. 2024. PMID: 38354535 Clinical Trial.
ALCAPA - the great masquerader.
Kumar SS, Sasikumar D, Ayyappan A, Krishnamoorthy KM, Dharan BS. Kumar SS, et al. Among authors: dharan bs. Acta Cardiol. 2024 Mar 21:1-3. doi: 10.1080/00015385.2024.2327141. Online ahead of print. Acta Cardiol. 2024. PMID: 38511526 No abstract available.
Early and Long-Term Clinical Outcomes of Ductal Stenting Versus Surgical Aortopulmonary Shunt Among Young Infants with Duct-Dependent Pulmonary Circulation.
Singh G, Gopalakrishnan A, Subramanian V, Sasikumar D, Sasidharan B, Dharan BS, Srinivasa Prasad BV, Menon S, Valaparambil A, Krishnamoorthy KM, Sivasubramonian S, Tharakan J. Singh G, et al. Among authors: dharan bs. Pediatr Cardiol. 2024 Apr;45(4):787-794. doi: 10.1007/s00246-024-03415-x. Epub 2024 Feb 15. Pediatr Cardiol. 2024. PMID: 38360920
86 results